InMed Pharmaceuticals Inc (INM)

[Aladdin80]

Yes, even for a small biotech developing novel technologies they're just painfully slow. So slow that missing milestones across all of the programs seems to be the only thing that they're accomplishing. EA is also sneaky in the way he'll slightly modify the language in presentation briefings from one to the next in an attempt to camouflage the repetitive can kicking.

I've sent a couple of recent inquiries since the call to our new IR spokesperson Mr. Payne, but I'm not holding my breath for any response. Mark my words the next NR will be financing news and as we know it will not be pretty. At this point I'd just really appreciate any honest data sets on biosynthesis. Outside of the biological burden mention in last yr's call, we have no clue what exactly happened that led to an exploration of path #2. To complicate things even further, we now have "several" paths that we're exploring. Whaaa? I mean this is critical info and changes everything from time lines to addtl R&D expenditures to other variables. Stakeholders aren't asking for the keys to the castle to want a little more information on such a radical change in the program. People should be demanding more transparency at this stage. Maybe they will once they dilute us again and reduce everyone's investment by adding another quarter billion shares.